Cytek Biosciences Revenue and Competitors

Claim your profile

Location

#8165

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Cytek Biosciences's estimated annual revenue is currently $119.7M per year.(i)
  • Cytek Biosciences received $Undisclosed in venture funding in September 2018.
  • Cytek Biosciences's estimated revenue per employee is $331,496
  • Cytek Biosciences's total funding is $144.3M.
  • Cytek Biosciences's current valuation is $1.8B. (January 2022)

Employee Data

  • Cytek Biosciences has 361 Employees.(i)
  • Cytek Biosciences grew their employee count by 25% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

Cytek Biosciences Inc. is a leading manufacturer and supplier of flow cytometry products and services. Cytek's compact, affordable instruments and wide ranging support offerings are used by researchers and clinicians all over the world. Flow cytometry is a powerful analytical tool used for identifying and quantifying cellular characteristics on a cell-by-cell basis up to tens of thousands of cells per second. This technology is used in research and clinical studies with various biomedical and therapeutic applications such as investigating the role of the body's immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients. Flow cytometry has many advantages over traditional microscopy since it enables the analysis of a greater number of cells in a fraction of the time. At Cytek, we are focused on accelerating the adoption of flow cytometry for one simple reason: to fuel scientific discovery. We have leveraged our highly experienced, best-in-the-business team to bring forth an innovative new class of flow cytometry solutions. These solutions deliver deep biological insights at an affordable price, provide high-end capabilities, and bring simplified workflows to more researchers than ever before. As a company, we also seek to maintain high ethical standards and a culture that values honesty, integrity and transparency in all that we do. Company decisions are driven by what is right for scientific discovery and customer support. We are committed to our employees, to the environment in which we live and to the communities we serve worldwide. Cytek is headquartered in Fremont, California with branch offices and distribution channels across the globe. For more information, visit www.cytekbio.com.

keywords:N/A

$144.3M

Total Funding

361

Number of Employees

$119.7M

Revenue (est)

25%

Employee Growth %

$1.8B

Valuation

N/A

Accelerator

Cytek Biosciences News

2022-04-17 - Can Cytek Biosciences, Inc. (NASDAQ:CTKB) Improve Its Returns?

That means that for every $1 worth of shareholders' equity, the company generated $0.01 in profit. Does Cytek Biosciences Have A Good Return On...

2022-04-17 - Analyzing Cytek Biosciences (NASDAQ:CTKB) and Nautilus ...

This table compares Nautilus Biotechnology and Cytek Biosciences' top-line revenue, earnings per share and valuation.

2022-04-17 - Cytek Biosciences, Inc. (NASDAQ:CTKB) CTO Sells $206800.00 in ...

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical...

2020-11-05 - Cytek Biosciences Closes $120M Series D Funding

Cytek Biosciences Inc., a Fremont, Calif.-based provider of cell analysis instrumentation and solutions, closed a $120m Series D funding round. The round was co-led by RA Capital and Hillhouse Capital, with OrbiMed and LYFE Capital also participating. Additionally, RA Capital and Hillhouse Capi ...

2020-11-05 - Cytek Biosciences Closes $120M Series D Funding

Cytek Biosciences Inc., a Fremont, Calif.-based provider of cell analysis instrumentation and solutions, closed a $120m Series D funding round. The round was co-led by RA Capital and Hillhouse Capital, with OrbiMed and LYFE Capital also participating. Additionally, RA Capital and Hillhouse Capi ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$35M3683%N/A
#2
$67.1M37034%N/A
#3
$153.5M372-1%N/A
#4
$67.8M374-26%N/A
#5
$66.2M38020%N/A

Cytek Biosciences Funding

DateAmountRoundLead InvestorsReference
2018-09-26$UndisclosedCNorthern Lights Ventures, LLCArticle